一品红：馥感啉颗粒获药物临床试验批准

Core Viewpoint - The company has received approval from the National Medical Products Administration for clinical trials of its drug, Fuganlin Granules, aimed at treating adult patients with Qi deficiency cold [1] Group 1: Company Developments - The company's wholly-owned subsidiary, Guangzhou Yipinhong Pharmaceutical Co., Ltd., is responsible for the drug's clinical trial application [1] - The approval allows the company to proceed with clinical trials for Fuganlin Granules, indicating progress in its product development pipeline [1] Group 2: Industry Context - The approval of new drugs is a critical step in the pharmaceutical industry, reflecting regulatory support for innovative treatments [1] - Conducting clinical trials is essential for validating the efficacy and safety of new medications, which can impact market competitiveness [1]